CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 12 enrolled
Drug / intervention
CNDO-109-AANK Cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01520558
NCT01520558Phase 2Unknown
CompareCT.gov

A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)

Coronado Biosciences, Inc.·interventional·Posted Jan 30, 2012·Updated Jun 29, 2017

In Brief

A Phase 2 clinical trial evaluating CNDO-109-AANK Cells for Acute Myeloid Leukemia. Targeting 12 participants across 4 sites.

Detailed Summary

This is a multi-center, open-label, non-controlled, non-randomized dose-escalating Phase 1 clinical study designed to examine the safety of infusing escalating doses of CNDO-109-Activated Allogeneic Natural Killer Cells-(from a first or second degree relative), after a preparatory chemotherapy regimen, in adult patients with acute myeloid leukemia (AML) who are in their first complete remission at the time of enrollment, are not candidates for stem cell transplant, and are considered to be at high risk for recurrence.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2UnknownOverdue
201220132014201520162017201820192020202120222023202420252026
First PostedJan 30, 2012
Enrollment StartDec 1, 2012
Primary CompletionMar 1, 2016
Study CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 14.4 years ago

Interventions

CNDO-109-AANK Cellsbiological

Single dose, infusion